Avantor® Reports Third Quarter 2026 Results

Avantor posts solid Q3 sales growth and swings to profit, but margin pressures persist.

What the company is saying

Avantor, Inc. is highlighting a return to year-over-year growth in the third quarter of 2026, with net sales of $1,698.3 million, a 4.6% increase, and organic growth of 5.2%. The company emphasizes exceeding internal expectations for both revenue and adjusted EPS, though it does not disclose those benchmarks. CEO Emmanuel Ligner frames the results as evidence of improved execution and a sharpened strategic focus, crediting associates for the turnaround. The narrative stresses robust free cash flow generation of $156.2 million, which management claims has strengthened the balance sheet. Segment commentary points to VWR Distribution & Services achieving 5.8% organic growth and Bioscience & Medtech Products returning to organic growth, both attributed to stronger end markets and execution. The company raises its full-year 2026 guidance for organic revenue growth, adjusted EPS, and free cash flow, projecting continued momentum. Margin commentary acknowledges pressures from unfavorable product mix and higher SG&A expenses in VWR, and flat margins in Bioscience & Medtech due to offsetting higher SG&A costs.

What the data suggests

The disclosed numbers show Avantor’s Q3 2026 net sales rose to $1,698.3 million, up 4.6% year-over-year, with organic growth of 5.2% after a 0.6% FX headwind. Net income improved sharply to $203.4 million from a net loss of $711.8 million a year earlier, and GAAP EPS reached $0.30, with adjusted EPS at $0.22. Adjusted net income was $146.4 million, slightly below last year’s $151.1 million, and adjusted EBITDA was $256.9 million, for a margin of 15.1%. Operating cash flow was $195.1 million and free cash flow $156.2 million. Segment data shows VWR Distribution & Services net sales of $1,233.8 million (5.0% reported, 5.8% organic), but adjusted operating income declined to $119.4 million from $132.0 million, with margin falling to 9.7% due to product mix and higher SG&A. Bioscience & Medtech Products net sales were $464.5 million (3.5% reported, 3.6% organic), adjusted operating income rose to $123.4 million, and margin held at 26.6%. Gross debt stood at $3,699.7 million, cash at $464.3 million, with GAAP net leverage at 9.6x and adjusted net leverage at 3.1x. The company raised 2026 guidance: organic revenue growth to +0.75% to +1.25%, adjusted EPS to $0.81–$0.83, and free cash flow to $525–$550 million. While the swing to profit and cash generation are clear positives, margin compression in VWR and flat margins in Bioscience & Medtech temper the overall improvement.

Analysis

The announcement presents a positive tone, highlighting a return to year-over-year growth, improved profitability, and strong cash flow. These claims are largely substantiated by detailed numerical disclosures for revenue, net income, EPS, EBITDA, and cash flow, supporting the realised improvement in financial performance. However, some narrative inflation is present: the CEO claims the company 'exceeded expectations' for revenue and adjusted EPS, but no actual consensus or guidance figures are disclosed for comparison. Phrases like 'robust free cash flow to strengthen the balance sheet' are qualitative and not directly tied to a measurable reduction in leverage or debt. The statement that VWR Distribution & Services achieved 'accelerating organic growth' is not supported by prior period organic growth rates, and the claim that Bioscience & Medtech Products 'returned to organic growth as expected' lacks explicit prior data or expectations. Most key results are realised and immediate, with only a small portion of the release devoted to forward-looking guidance for the remainder of 2026. There is no evidence of a large new capital outlay or long-dated, uncertain returns in this release.

Risk flags

• ●Margin pressure is evident in the VWR Distribution & Services segment, where adjusted operating income margin declined to 9.7% due to unfavorable product mix and higher SG&A expenses. Sustained margin compression could limit earnings growth even as sales rise.
• ●Despite strong free cash flow, Avantor’s gross debt remains high at $3,699.7 million, resulting in a GAAP net leverage ratio of 9.6x. Elevated leverage increases financial risk and limits flexibility, especially if operating performance weakens.
• ●Management claims of 'exceeding expectations' and 'accelerating growth' are not substantiated by disclosed benchmarks or prior period organic growth rates. This lack of transparency on internal targets and comparative metrics introduces uncertainty about the true scale of outperformance.
• ●Adjusted net income and operating income in some segments declined year-over-year, despite overall sales growth. If cost pressures persist, future profitability improvements may be constrained.
• ●The company’s updated guidance assumes a modest FX tailwind and lower net interest expense, but adverse currency moves or higher rates could negatively impact results.

Bottom line

Avantor’s Q3 2026 results show a clear return to profitability, with net sales up 4.6% to $1,698.3 million and a swing from a $711.8 million loss to $203.4 million in net income. Free cash flow was strong at $156.2 million, supporting a raised full-year outlook for revenue, EPS, and cash generation. However, margin pressures in the VWR Distribution & Services segment and flat margins in Bioscience & Medtech Products signal ongoing cost challenges. Gross debt remains elevated at $3.7 billion, keeping leverage high and financial risk above average. Management’s narrative of exceeding expectations is not fully supported by disclosed benchmarks, and some segment profitability metrics declined. Investors should focus on whether margin recovery materializes and leverage is reduced in coming quarters. The most important takeaway is that while topline and net income trends have improved, margin and leverage risks remain material and warrant close monitoring.

Announcement summary

(NYSE:AVTR) Avantor, Inc. reported net sales of $1,698.3 million for the third quarter of 2026, representing a 4.6% increase compared to the third quarter of 2025, with organic sales growth of 5.2%. Diluted GAAP earnings per share (EPS) were $0.30, and adjusted EPS was $0.22 for the quarter. Net income rose to $203.4 million from a net loss of $711.8 million in the prior-year period, with a net income margin of 12.0%. Adjusted net income was $146.4 million, compared to $151.1 million in the third quarter of 2025. Adjusted EBITDA reached $256.9 million, with an adjusted EBITDA margin of 15.1%. Operating income was $139.5 million, with an operating income margin of 8.2%, while adjusted operating income was $227.6 million and adjusted operating income margin was 13.4%. VWR Distribution & Services segment reported net sales of $1,233.8 million, up from $1,175.0 million, a 5.0% increase (5.8% organic), with adjusted operating income of $119.4 million and margin of 9.7%. Bioscience & Medtech Products segment reported net sales of $464.5 million, up from $448.8 million, a 3.5% increase (3.6% organic), with adjusted operating income of $123.4 million and margin of 26.6%. As of September 30, 2026, total gross debt was $3,699.7 million and cash and cash equivalents were $464.3 million. GAAP net leverage was 9.6x and adjusted net leverage was 3.1x. Operating cash flow for the quarter was $195.1 million, and free cash flow was $156.2 million. Updated fiscal 2026 guidance includes organic revenue growth of +0.75% to +1.25%, adjusted EBITDA margin of 14.8% to 15.3%, adjusted EPS of $0.81 to $0.83, and free cash flow of $525 million to $550 million. The company assumes reported revenue growth of +1.5% to +2.0%, a blended EUR/USD exchange rate of 1.15, net interest expense expected to decline modestly versus 2025, an adjusted effective tax rate between 22.0% and 22.5%, and a fully diluted share count of 679 million shares. Emmanuel Ligner, President and Chief Executive Officer, stated that the company returned to year-over-year growth in the third quarter, exceeding expectations for revenue and adjusted EPS, and generated robust free cash flow to strengthen the balance sheet. VWR Distribution & Services achieved accelerating organic growth of 5.8%, and Bioscience & Medtech Products returned to organic growth as expected. Adjusted operating income margin in VWR Distribution & Services declined due to unfavorable product mix and higher SG&A expenses, partially offset by higher sales volume, while Bioscience & Medtech Products margin was flat due to higher sales volume and commercial excellence, partially offset by higher SG&A expenses. The company hosted a conference call on October 28, 2026, at 8:00 a.m. Eastern Time to discuss these results.

Disagree with this article?